ACTRIMS 2022 | Potential of BTK inhibitors in MS

Rochelle Benoit, MS, Memorial University of Newfoundland, St. John’s, Newfoundland, Canada, discusses the advantage of Bruton’s tyrosine kinase inhibitors (BTKis) for the treatment of multiple sclerosis (MS). Thus far, BTKis have not been exhibiting immunosuppressive qualities in MS. Providing a disease-modifying therapy that can treat MS disease activity without compromising the immune system would be significantly beneficial for the treatment of this patient population. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.